Literature DB >> 24108461

A critical role for Lyn kinase in strengthening endothelial integrity and barrier function.

Jingyan Han1, Guoying Zhang, Emily J Welch, Ying Liang, Jian Fu, Stephen M Vogel, Clifford A Lowell, Xiaoping Du, David A Cheresh, Asrar B Malik, Zhenyu Li.   

Abstract

The Src family kinases (SFKs) c-Src and Yes mediate vascular leakage in response to various stimuli including lipopolysaccharide (LPS) and vascular endothelial growth factor (VEGF). Here, we define an opposing function of another SFK, Lyn, which in contrast to other SFKs, strengthens endothelial junctions and thereby restrains the increase in vascular permeability. Mice lacking Lyn displayed increased mortality in LPS-induced endotoxemia and increased vascular permeability in response to LPS or VEGF challenge compared with wild-type littermates. Lyn knockout mice repopulated with wild-type bone marrow-derived cells have higher vascular permeability than wild-type mice, suggesting a role of endothelial Lyn in the maintenance of the vascular barrier. Small interfering RNA-mediated down-regulation of Lyn disrupted endothelial barrier integrity, whereas expression of a constitutively active mutant of Lyn enhanced the barrier. However, down-regulation of Lyn did not affect LPS-induced endothelial permeability. We demonstrate that Lyn association with focal adhesion kinase (FAK) and phosphorylation of FAK at tyrosine residues 576/577 and 925 were required for Lyn-dependent stabilization of endothelial adherens junctions. Thus, in contrast to c-Src and Yes, which increase vascular permeability in response to stimuli, Lyn stabilizes endothelial junctions through phosphorylation of FAK. Therefore, therapeutics activating Lyn kinase may strengthen the endothelial barrier junction and hence have anti-inflammatory potential.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24108461      PMCID: PMC3862279          DOI: 10.1182/blood-2013-03-491423

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

Review 1.  Dasatinib: an anti-tumour agent via Src inhibition.

Authors:  Antonio Gnoni; Ilaria Marech; Nicola Silvestris; Angelo Vacca; Vito Lorusso
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

2.  Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues.

Authors:  Nathalie Lambeng; Yann Wallez; Christine Rampon; Francine Cand; Georges Christé; Danielle Gulino-Debrac; Isabelle Vilgrain; Philippe Huber
Journal:  Circ Res       Date:  2005-01-20       Impact factor: 17.367

3.  Inhibition of the Src and Jak kinases protects against lipopolysaccharide-induced acute lung injury.

Authors:  Mariano Severgnini; Satoe Takahashi; Powen Tu; George Perides; Robert J Homer; Jhung W Jhung; Deepa Bhavsar; Brent H Cochran; Amy R Simon
Journal:  Am J Respir Crit Care Med       Date:  2005-01-21       Impact factor: 21.405

4.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

Authors:  Hagop Kantarjian; Ricardo Pasquini; Nelson Hamerschlak; Philippe Rousselot; Jerzy Holowiecki; Saengsuree Jootar; Tadeusz Robak; Nina Khoroshko; Tamas Masszi; Aleksander Skotnicki; Andrzej Hellmann; Andrey Zaritsky; Anatoly Golenkov; Jerald Radich; Timothy Hughes; Athena Countouriotis; Neil Shah
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

Review 5.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

6.  The Src family kinases and protein kinase C synergize to mediate Gq-dependent platelet activation.

Authors:  Binggang Xiang; Guoying Zhang; Lucia Stefanini; Wolfgang Bergmeier; T Kent Gartner; Sidney W Whiteheart; Zhenyu Li
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

7.  Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.

Authors:  Kimmo Porkka; H Jean Khoury; Ronald L Paquette; Yousif Matloub; Ritwik Sinha; Jorge E Cortes
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

8.  Tyrosine phosphorylation of vascular endothelial cadherin and the regulation of microvascular permeability.

Authors:  Fiemu E Nwariaku; Zijuan Liu; Xudong Zhu; Richard H Turnage; George A Sarosi; Lance S Terada
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982

9.  TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia.

Authors:  Ping Gong; Daniel J Angelini; Shiqi Yang; Guanjun Xia; Alan S Cross; Dean Mann; Douglas D Bannerman; Stefanie N Vogel; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2008-03-07       Impact factor: 5.157

10.  Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling.

Authors:  Brian P Eliceiri; Xose S Puente; John D Hood; Dwayne G Stupack; David D Schlaepfer; Xiaozhu Z Huang; Dean Sheppard; David A Cheresh
Journal:  J Cell Biol       Date:  2002-04-01       Impact factor: 10.539

View more
  26 in total

1.  Time-Variant SRC Kinase Activation Determines Endothelial Permeability Response.

Authors:  Jennifer E Klomp; Mark Shaaya; Jacob Matsche; Rima Rebiai; Jesse S Aaron; Kerrie B Collins; Vincent Huyot; Annette M Gonzalez; William A Muller; Teng-Leong Chew; Asrar B Malik; Andrei V Karginov
Journal:  Cell Chem Biol       Date:  2019-05-23       Impact factor: 8.116

2.  Shockingly: the loss of Lyn leads to leakiness.

Authors:  Seth J Corey; Regina M Day
Journal:  Blood       Date:  2013-12-12       Impact factor: 22.113

3.  The Src family tyrosine kinases src and yes have differential effects on inflammation-induced apoptosis in human pulmonary microvascular endothelial cells.

Authors:  Leif D Nelin; Hilary A White; Yi Jin; Jennifer K Trittmann; Bernadette Chen; Yusen Liu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-02-26       Impact factor: 5.464

Review 4.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 5.  Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability.

Authors:  Yulia A Komarova; Kevin Kruse; Dolly Mehta; Asrar B Malik
Journal:  Circ Res       Date:  2017-01-06       Impact factor: 17.367

6.  Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.

Authors:  Julien Mahé; Emilie Patras de Campaigno; Anne-Laure Chené; Jean-Louis Montastruc; Fabien Despas; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2018-08-05       Impact factor: 4.335

7.  Adhesion structures in leukemia cells and their regulation by Src family kinases.

Authors:  Pavla Röselová; Adam Obr; Aleš Holoubek; Dana Grebeňová; Kateřina Kuželová
Journal:  Cell Adh Migr       Date:  2017-08-18       Impact factor: 3.405

8.  MARCKS-related protein regulates cytoskeletal organization at cell-cell and cell-substrate contacts in epithelial cells.

Authors:  Christina M Van Itallie; Amber Jean Tietgens; Angel Aponte; Marjan Gucek; Alexander X Cartagena-Rivera; Richard S Chadwick; James M Anderson
Journal:  J Cell Sci       Date:  2018-02-02       Impact factor: 5.285

9.  Immune Defense Protein Expression in Highly Purified Mouse Lung Epithelial Cells.

Authors:  Meenal Sinha; Clifford A Lowell
Journal:  Am J Respir Cell Mol Biol       Date:  2016-06       Impact factor: 6.914

10.  SH2 domain-containing protein tyrosine phosphatase 2 and focal adhesion kinase protein interactions regulate pulmonary endothelium barrier function.

Authors:  Havovi Chichger; Julie Braza; Huetran Duong; Elizabeth O Harrington
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.